戻る Agenda
Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?
Session Chair(s)
Stephen Keith, MD, MPH
Senior Medical Director, Medical and Scientific Management, Clinical Solutions
Syneos Health, United States
With combined experience running studies and drafting FDA rules, this panel will show why guidance on trial diversity has not produced results. Audience polling will help illuminate how incentives can translate guidance into thoughtful action.
Learning Objective : Characterize obstacles that rendered FDA guidance on clinical trial diversity ineffective thus far; Identify federal initiatives, such as the Orphan Drug Act, that have successfully galvanized industry in other contexts; Define incentives that might invigorate industry-led minority enrollment programs; Evaluate an audience ranking of proposed incentives using real-time digital polling.
Speaker(s)
Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?
Peter J. Pitts
Center for Medicine in the Public Interest (CMPI), United States
President
Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?
David H Strauss, MD
Columbia University , United States
Special Lecturer
Is There a Role for Federal Incentives to Stimulate Greater Diversity in Clinical Trials?
Kimberly Y. Smith, MD, MPH
ViiV Healthcare, United States
Chief Scientific Officer, Senior Vice President, Head of R&D